GRAIL: A Tissue-free Platform to Revolutionize Cancer Care
Time: 9:40 am
day: Day Two AM
Details:
- GRAIL’s methylation solution is uniquely suited for the detection, quantification, and classification of cancer through a non-invasive blood draw
- New data demonstrate platform utility across the patient care continuum to advance biopharma therapeutic strategies
- A novel Clinical Trial Assay leveraging GRAIL methylation for risk stratification in Stage I Lung Cancer
